BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011;12:300-309. [PMID: 21346780 DOI: 10.1038/gene.2011.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29:545-553. [PMID: 24090188 DOI: 10.1111/jgh.12398] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 12.4] [Reference Citation Analysis]
2 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
3 Peymani P, Yeganeh B, Sabour S, Geramizadeh B, Fattahi MR, Keyvani H, Azarpira N, Coombs KM, Ghavami S, Lankarani KB. New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). Can J Physiol Pharmacol 2016;94:613-9. [PMID: 26998724 DOI: 10.1139/cjpp-2015-0507] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
4 Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, Doehring A. Single and combined IL28B , ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Pharmacogenomics 2011;12:1729-40. [DOI: 10.2217/pgs.11.99] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
5 Zhang T, Zhang Z, Zhang Y, Ye J, Li X. A Lower PBMC Estrogen Receptor α Gene Expression in Chronic Hepatitis B Is Associated with a Sustained Virological Response to Pegylated Interferon. J Interferon Cytokine Res 2016;36:120-8. [PMID: 26485345 DOI: 10.1089/jir.2014.0223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Fernández-rodríguez A, Rallón N, Berenguer J, Jiménez-sousa MA, Cosín J, Guzmán-fulgencio M, Restrepo C, Lopez JC, García-álvarez M, Miralles P, Soriano V, Benito JM, Resino S. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. AIDS 2013;27:163-73. [DOI: 10.1097/qad.0b013e32835c11e8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Luo Y, Jin C, Ling Z, Mou X, Zhang Q, Xiang C. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene 2013;513:292-6. [DOI: 10.1016/j.gene.2012.10.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
8 Tajir M, Elmachad M, Kabbaj N, Laarabi FZ, Barkat A, Amrani N, Sefiani A. Frequency of IL28B rs12979860 single-nucleotide polymorphism alleles in newborn infants and in patients with chronic hepatitis C in Morocco. Genet Test Mol Biomarkers 2012;16:981-3. [PMID: 22509814 DOI: 10.1089/gtmb.2011.0353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Olmedo DB, Cader SA, Porto LC. IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. J Med Virol 2015;87:1702-15. [PMID: 25970604 DOI: 10.1002/jmv.24227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6. [PMID: 23298311 DOI: 10.1186/1741-7015-11-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
11 Wen S, Cheng L, Hsu J, Lai H, Shih P, Tsai C, Kuo W. Assessment of baseline pretreatment factors and on-treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Advances in Digestive Medicine 2017;4:4-11. [DOI: 10.1002/aid2.12004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wu LS, Wang H, Geng XP. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Exp Ther Med 2012;3:200-6. [PMID: 22969869 DOI: 10.3892/etm.2011.385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
13 Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis. Gene 2012;507:27-35. [PMID: 22842190 DOI: 10.1016/j.gene.2012.07.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
14 Delvaux N, da Costa VD, da Costa MM, Lampe E. Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients. J Virol Methods 2015;220:1-4. [PMID: 25863261 DOI: 10.1016/j.jviromet.2015.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yen YH, Wang JC, Hung CH, Lu SN, Wang JH, Hu TH, Kee KM, Hsiao CC, Lee CM. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. J Formos Med Assoc 2015;114:652-8. [PMID: 23810703 DOI: 10.1016/j.jfma.2013.04.013] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Zhong YW, Zhang HF, Shi YM, Li YL, Chu F, Xu ZQ, Chen DW, Gan Y, Wang FC, Gu ML, Dong Y, Zhu SS, Shi C, Fan HH, Zhang XC, Zhang M. IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C. Int J Biol Sci 2016;12:1357-62. [PMID: 27877087 DOI: 10.7150/ijbs.16220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res 2014;34:479-97. [PMID: 24555572 DOI: 10.1089/jir.2013.0113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
18 Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, duCros P. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:540-550. [PMID: 22807600 DOI: 10.2471/blt.11.097147] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
19 Chinnaswamy S, Chatterjee S, Boopathi R, Mukherjee S, Bhattacharjee S, Kundu TK. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription. PLoS One 2013;8:e75495. [PMID: 24116050 DOI: 10.1371/journal.pone.0075495] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
20 Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol 2018;24:311-8. [PMID: 29865774 DOI: 10.3350/cmh.2017.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
21 米寅, 高英堂, 焦晓磊, 杜智. IL-28B基因多态性与丙型肝炎易感性的关系. 世界华人消化杂志 2013; 21(2): 182-187 [DOI: 10.11569/wcjd.v21.i2.182] [Reference Citation Analysis]
22 Schlecker C, Ultsch A, Geisslinger G, Lötsch J. The pharmacogenetic background of hepatitis C treatment. Mutat Res. 2012;Epub ahead of print. [PMID: 22409946 DOI: 10.1016/j.mrrev.2012.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, Xie Q. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population: IL28B genetic variations in HCV patients. Journal of Digestive Diseases 2015;16:90-7. [DOI: 10.1111/1751-2980.12202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
24 Tipu I, Marriage F, Farooqi ZU, Platt H, Athar MA, Day PJ, Short A. The IFN-λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. Hepat Mon 2014;14:e15076. [PMID: 24734091 DOI: 10.5812/hepatmon.15076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lyoo K, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, Bae SH, Choi JY, Choi SW, Shin EC. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol. 2011;52:363-366. [PMID: 21907615 DOI: 10.1016/j.jcv.2011.08.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
26 Chen H, Zhang Y, Huang P, Xu Y, Wang J, Su J, Yu R. Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. J Biomed Res 2014;28:476-83. [PMID: 25469117 DOI: 10.7555/JBR.28.20130142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Ekstrom V, Kumar R, Zhao Y, Yee ML, Sung C, Toh D, Loh PY, Tan J, Teo EK, Chow WC. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. Gastroenterol Rep (Oxf) 2017;5:208-12. [PMID: 28852525 DOI: 10.1093/gastro/gow033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7. [PMID: 26835876 DOI: 10.1111/liv.13082] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
29 Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, Shi WX, Du Z. The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon 2014;14:e18793. [PMID: 25337144 DOI: 10.5812/hepatmon.18793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
30 Cui Q, Zhang YX, Su J, Chen X, Ding K, Lei N, Liu Y, Li J, Zhang Y, Yu RB. Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect Genet Evol. 2011;11:1682-1689. [PMID: 21742059 DOI: 10.1016/j.meegid.2011.06.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
31 Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, Wang HY, Chen JJ, Yang JC, Knox SJ, Gao B, Garrison KL, Mo H, Pang PS, Hsu YC, Hu TH, Chu CJ, Kao JH. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol 2016;31:1323-9. [PMID: 26841930 DOI: 10.1111/jgh.13305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
32 Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol 2017;206:165-74. [PMID: 28214926 DOI: 10.1007/s00430-017-0497-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
33 Kawaguchi-suzuki M, Frye RF. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. Pharmacotherapy 2014;34:185-201. [DOI: 10.1002/phar.1349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
34 Lin C, Sheen I, Jeng W, Huang C, Huang C, Chen J. Patients younger than forty years old with hepatitis C virus genotype–1 chronic infection had treatment responses similar to genotype–2 infection and not related to interleukin–28B polymorphism. Annals of Hepatology 2013;12:62-9. [DOI: 10.1016/s1665-2681(19)31386-9] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
35 Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. PLoS One 2012;7:e48217. [PMID: 23173032 DOI: 10.1371/journal.pone.0048217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 da Silva Conde SR, Soares Monteiro JC, Silva Dos Santos BT, Fonseca Filgueiras NK, de Almeida Lins PA, Bonfim Freitas F, da Silva Graça E, Demachki S, Ferreira de Araújo MT, Ishak R, Rosário Vallinoto AC. SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment. Biomed Res Int 2014;2014:748606. [PMID: 24678513 DOI: 10.1155/2014/748606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
37 Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015;Epub ahead of print. [PMID: 25918016 DOI: 10.1038/tpj.2015.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]